China State Council’s new directive herald key changes for Chinese R&D

China State Council’s new directive herald key changes for Chinese R&D

In a surprise move, the State Council in China has recently released a directive announcing its view on reforming the drug and medical device review and approval process in China. The State Council oversees the Chinese Food and Drug Administration (CFDA), and it is noteworthy that these changes were announced at a high level, reflecting […]

Read More

September 1st, 2015

Update to Australia’s R&D tax incentive

The R&D Tax Incentive is a targeted, generous and easy to access entitlement program that helps businesses offset some of the costs of doing R&D. The Program aims to help more businesses do R&D and innovate. It is a broad-based entitlement program. This means that it is open to firms of all sizes in all […]

Read More

June 2nd, 2014

R&D tax incentives for George Clinical services

There’s no better time to be working with us. The Australian Tax Office will provide a tax incentive to encourage R&D activities in Australia, jointly administered by AusIndustry. Companies with < $20m per annum turnover can be eligible for 45% refundable tax offset; and other companies can be eligible for a non-refundable 40% tax offset. […]

Read More

August 28th, 2013

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network